Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancers
Posted: 23 October 2023 Starpharma (ASX: SPL, OTCQX: SPHRY) today announces the final positive results from its completed Phase 2 open-label clinical trial of DEP® cabazitaxel. The trial met its objectives, with endpoints demonstrating positive anti-tumour efficacy of DEP® cabazitaxel…
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
Posted: 23 October 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces excellent new clinical data from the TACTI-002 / KEYNOTE-798…
A better ‘map’ of the lights you see when you close your eyes can improve ‘bionic eye’ outcomes
Posted: 17 October 2023 Researchers at Monash University have identified a new way of mapping ‘phosphenes’ – the visual perception of the bright flashes we see when no light is entering the eye – to improve the outcome…
New $15m frontier technology centre to develop next-generation cancer drugs
Posted: 17 October 2023 Australia has a new frontier technology centre that is set to revolutionise drug development for metastatic prostate cancer and childhood neuroblastoma. The Australian Centre for Targeted Therapeutics (ACTT) has been awarded $15 million from…
A well-established drug can improve hand osteoarthritis symptoms: study
Posted: 17 October 2023 Relief could be on the way for people with painful hand osteoarthritis after a Monash University and Alfred Health-led study found an affordable existing drug can help. Until now there has been no effective…
Australian-first trial to transform lives of children with a severe immune deficiency disorder
Posted: 17 October 2023 A cure for a severe immune deficiency disorder in children that makes them extremely vulnerable to infections will be offered in Australia for the first time under a cutting-edge gene therapy trial. Murdoch Children’s…
Melbourne invention brings new hope for rheumatoid arthritis
Posted: 17 October 2023 A new nerve treatment invented by Melbourne researchers at the Bionics Institute is bringing hope to people with rheumatoid arthritis. The tiny piece of ground-breaking technology – the size of a thumbnail – could…
Global non-profit CARB-X awards more than AUD$2.6 million to University of Melbourne’s Doherty Institute to fight antibiotic resistance
Posted: 17 October 2023 University of Melbourne researchers from the Peter Doherty Institute for Infection and Immunity (Doherty Institute) are developing a world-first treatment for antibiotic-resistant community-acquired bacterial pneumonia (CABP). The AUD$2.68M (US$1.75M) award by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator…
Cartherics appoints new Chief Scientific Officer
Posted: 17 October 2023 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has appointed Dr Walid Azar as Chief Scientific Officer (CSO), effective immediately.…
PROOF-OF-CONCEPT CLINICAL TRIAL SUCCESSFULLY COMPLETED WITH LAT8881
Posted: 17 October 2023 Lateral Pharma has successfully completed its LAT8881 Phase 1b clinical trial in patients with chronic lumbar radicular pain (a condition commonly referred to as “sciatica”).1,2 The results from this study have demonstrated clinical “proof-of-concept”…
OPTISCAN ANNOUNCES KEY APPOINTMENTS FOR US OPERATION
Posted: 13 October 2023 Optiscan Imaging Limited (ASX: OIL) is pleased to advise a number of key leadership appointments as it pursues further growth and expansion of its subsidiary, Optiscan Imaging, Inc. in the United States. The Company…
When cells go boom: study reveals inflammation-causing gene carried by millions
Posted: 12 October 2023 Researchers have found that a genetic change that increases the risk of inflammation, through a process described as ‘explosive’ cell death, is carried by up to 3% of the global population. The WEHI-led study…
